Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates
RSC Medicinal Chemistry · 2025 · 16 (1) · 50-62
DOI: 10.1039/d4md00637b ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Medicinal Chemistry, 2025. Verfasst von Qiang Yang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Brilliant BioConsultation Ellicott City MD 21043 USA Brilliant.BioConsult@gmail.com. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Fc-glycan-specific ADC is a significant advance in site-specific ADCs for cancer therapy. Notably, JSKN003 and IBI343 have demonstrated promising results in phase 1 clinical trials and are advancing into phase 3 studies.
Autor:innen und Institutionen
- Brilliant BioConsultation Ellicott City MD 21043 USA Brilliant.BioConsult@gmail.com.
- ChemBind LLC Atlanta GA 30303 USA yliu@chembind.com.
ORCID-Profile: Qiang Yang, Yunpeng Liu
Zitieren
APA
Yang, Q., & Liu, Y. (2025). Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates. RSC Medicinal Chemistry, 16(1), 50-62. https://doi.org/10.1039/d4md00637b
Vancouver
Yang Q, Liu Y. Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates. RSC Medicinal Chemistry. 2025;16(1):50-62. doi:10.1039/d4md00637b
BibTeX
@article{Yang2025,
author = {Yang, Qiang and Liu, Yunpeng},
title = {Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates},
journal = {RSC Medicinal Chemistry},
year = {2025},
volume = {16},
number = {1},
pages = {50--62},
doi = {10.1039/d4md00637b}
}
EUVIMED